- Home
- TASK vs VERA Comparison
TASK vs VERA Comparison
Compare TASK & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TASK
- VERA
- Stock Information
- Founded
- TASK 2008
- VERA 2016
- Country
- TASK United States
- VERA United States
- Employees
- TASK N/A
- VERA N/A
- Industry
- TASK Retail: Computer Software & Peripheral Equipment
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- TASK Technology
- VERA Health Care
- Exchange
- TASK Nasdaq
- VERA Nasdaq
- Market Cap
- TASK 1.5B
- VERA 1.4B
- IPO Year
- TASK 2021
- VERA 2021
- Fundamental
- Price
- TASK $17.39
- VERA $22.02
- Analyst Decision
- TASK Buy
- VERA Buy
- Analyst Count
- TASK 5
- VERA 8
- Target Price
- TASK $17.40
- VERA $64.29
- AVG Volume (30 Days)
- TASK 234.9K
- VERA 1.6M
- Earning Date
- TASK 08-07-2025
- VERA 08-05-2025
- Dividend Yield
- TASK N/A
- VERA N/A
- EPS Growth
- TASK 21.25
- VERA N/A
- EPS
- TASK 0.67
- VERA N/A
- Revenue
- TASK $1,101,465,000.00
- VERA N/A
- Revenue This Year
- TASK $19.40
- VERA N/A
- Revenue Next Year
- TASK $11.62
- VERA N/A
- P/E Ratio
- TASK $25.96
- VERA N/A
- Revenue Growth
- TASK 19.04
- VERA N/A
- 52 Week Low
- TASK $10.57
- VERA $18.53
- 52 Week High
- TASK $19.60
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- TASK 61.31
- VERA 51.71
- Support Level
- TASK $17.19
- VERA $21.15
- Resistance Level
- TASK $17.66
- VERA $23.81
- Average True Range (ATR)
- TASK 0.19
- VERA 1.07
- MACD
- TASK 0.02
- VERA 0.19
- Stochastic Oscillator
- TASK 61.65
- VERA 60.75
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.